New Rhein

New Rhein is a venture capital firm focused on healthcare therapeutics and medical devices. Its partners and associates are former industry executives with operational and transactional experience. New Rhein invests in businesses that utilize proven products in new applications (e.g., new indications, new dosage forms, 505(b2)). The company compiles syndicates of operationally focused investors who together bring a wealth of experience and a broad network of relationships to support its portfolio companies in the development, regulatory, reimbursement, marketing, and/or contract manufacturing. New Rhein provides an understanding of what would be attractive to strategic partners and works backward to help its portfolio companies build their value proposition. Prior New Rhein investments have included ophthalmic pharmaceuticals, molecular diagnostics, and respiratory drug/device inhalers.

New Rhein, established in 2011 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Seed investments across Biotechnology, Health Care, Medical, Financial Services, Banking, Pharmaceutical, Manufacturing, Medical Device, Health Diagnostics, Consumer. The organization boasts a portfolio of 9 investments, with an average round size of $20.4M and 3 successful exits. Their recent investments include Chase Pharmaceuticals, Andera Partners, Cipla, Biocartis, Johnson & Johnson Development Corporation. The highest investment round they participated in was $7.1B. Among their most notable exits are Chase Pharmaceuticals and Andera Partners. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.